Life Sciences IP Due Diligence

Your Complete Guide for M&As, Licensing, and Other Collaborations

Monday, June 26, 2006

About

IP due diligence is now a central concern and struggle for companies in life science-related industries, due to the substantial growth of mergers and acquisitions, spin-outs, and divestitures, as well as the evolving role of licensing and collaborative arrangements. Because IP - particularly patents - are the key drivers in these deals, you must be competent in conducting proper due diligence and valuation assessments that enable you to complete deals and transactions essential to the development of new products and maximize profit potential.

Quite simply, general IP due diligence and valuation principles are not enough. To truly learn everything about the IP portfolio tied to a transaction - the validity, the claims, the potential lawsuits - and assess the portfolio's value, in-house counsel and business development executives must adapt to the latest from the courts, legislators, and regulators, including Integra, Hatch-Waxman reform, and yet-to-be-released FDA regulations and reporting requirements. Valuation is pivotal: You need a working understanding of the extent to which the final valuation assessment factors into your due diligence process. If your due diligence is not properly conducted, your client runs the risk of loss of reputation, loss of profits, or even ruin.

The publication from the 2nd National Conference on Life Sciences IP Due Diligence: Your Complete Guide for M&As, Licensing, and Other Collaborations will bring you thoughtful, targeted, and in-depth due diligence and valuation analysis from leading in-house and business development executives for life science companies, and expert attorneys and financial analysts from the life science sector. Within the presentations, you will find first-hand, practical, and comprehensive information on:
  • How the landscape of due diligence will change based on the latest legislative and regulatory reforms
  • Requesting and reviewing the information emphasized in the practical due diligence checklist
  • The FDA regulatory exclusivities that must be considered in any transaction
  • The methodologies used when evaluating proprietary biopharmaceutical products
  • Early-stage valuation v. late-stage valuation of compounds and companies
  • Overcoming ethical challenges in life sciences IP due diligence and valuation
Other highlights of this program include:
  • How do you address the target's prior contractual obligations and pending or future disputes?
  • How do you successfully uncover issues with ownership rights and inventorship?
  • How do you analyze rights in patents resulting from sponsored research?

Contents & Contributors

About

IP due diligence is now a central concern and struggle for companies in life science-related industries, due to the substantial growth of mergers and acquisitions, spin-outs, and divestitures, as well as the evolving role of licensing and collaborative arrangements. Because IP - particularly patents - are the key drivers in these deals, you must be competent in conducting proper due diligence and valuation assessments that enable you to complete deals and transactions essential to the development of new products and maximize profit potential.

Quite simply, general IP due diligence and valuation principles are not enough. To truly learn everything about the IP portfolio tied to a transaction - the validity, the claims, the potential lawsuits - and assess the portfolio's value, in-house counsel and business development executives must adapt to the latest from the courts, legislators, and regulators, including Integra, Hatch-Waxman reform, and yet-to-be-released FDA regulations and reporting requirements. Valuation is pivotal: You need a working understanding of the extent to which the final valuation assessment factors into your due diligence process. If your due diligence is not properly conducted, your client runs the risk of loss of reputation, loss of profits, or even ruin.

The publication from the 2nd National Conference on Life Sciences IP Due Diligence: Your Complete Guide for M&As, Licensing, and Other Collaborations will bring you thoughtful, targeted, and in-depth due diligence and valuation analysis from leading in-house and business development executives for life science companies, and expert attorneys and financial analysts from the life science sector. Within the presentations, you will find first-hand, practical, and comprehensive information on:
  • How the landscape of due diligence will change based on the latest legislative and regulatory reforms
  • Requesting and reviewing the information emphasized in the practical due diligence checklist
  • The FDA regulatory exclusivities that must be considered in any transaction
  • The methodologies used when evaluating proprietary biopharmaceutical products
  • Early-stage valuation v. late-stage valuation of compounds and companies
  • Overcoming ethical challenges in life sciences IP due diligence and valuation
Other highlights of this program include:
  • How do you address the target's prior contractual obligations and pending or future disputes?
  • How do you successfully uncover issues with ownership rights and inventorship?
  • How do you analyze rights in patents resulting from sponsored research?

Contents & Contributors


DEVELOPING A PRACTICAL IP DUE DILIGENCE STRATEGY IN LIGHT OF RECENT CASE LAW AND LEGISLATIVE REFORM
Rochelle K. Seide, Arent Fox PLLC

DEVELOPING A PRACTICAL IP DUE DILIGENCE STRATEGY IN LIGHT OF USPTO RULEMAKING
Reza Green, Novo Nordisk

THE PRACTICAL DUE DILIGENCE CHECKLIST: THE INFORMATION YOU CAN'T AFFORD NOT TO REQUEST AND REVIEW
Mark S. Ellinger, Fish & Richardson P.C.
Marc S. Friedman, Sills Cummis Epstein & Gross PC
Robert Silverman, Millennium Pharmaceuticals

A BUYER'S GUIDE TO MANAGING THE DUE DILIGENCE PROCESS
Jeffrey L. Quillen, Foley Hoag LLP

LIFE SCIENCES IP DUE DILIGENCE: PENDING AND FUTURE DISPUTES
Brian P. Waldman, Arent Fox PLLC

IMPACT OF RECENT DEVELOPMENTS IN PATENT DURATION AND LIFE CYCLE MANAGEMENT ON DUE DILIGENCE ASSESSMENTS
Adda C. Gogoris, Darby & Darby

ANALYZING RIGHTS IN PATENTS RESULTING FROM SPONSORED RESEARCH
Kathleen Sybert, Clinical Technology Transfer Group, P.L.L.C.

EVALUATING THE SCOPE, BREADTH, AND VALIDITYOF THE TARGET'S PATENTS
Michele C. Bosch, Finnegan, Henderson, Farabow, Garrett & Dunner LLP

PATENT OPINIONS IN THE AFTERMATH OF KNORR-BREMSE
Vineet Kohli, Merck & Co., Inc.

OVERCOMING OBSTACLES IDENTIFIED IN THE IP DUE DILIGENCE
PROCESS Beth E. Arnold, Foley Hoag LLP

FROM THE TARGET'S PERSPECTIVE: THE SELLER'S DUE DILIGENCE OBLIGATIONS
Noemi (Nicky) Espinosa, Dechert LLP
Todd E. Garabedian, Wiggin and Dana LLP
Kelly L. McDow-Dunham, Proctor & Gamble Company

CONDUCTING DUE DILIGENCE FOR THE LICENSING OF PHARMACEUTICAL AND BIOTECH IP
Stanton J. Lovenworth, Dewey Ballantine LLP

CONDUCTING DUE DILIGENCE FOR THE LICENSING OF PHARMACEUTICAL AND BIOTECH IP
Thomas G. Plant, Eli Lilly and Company

CONDUCTING DUE DILIGENCE FOR THE LICENSING OF PHARMACEUTICAL AND BIOTECH IP
Mark F. Radcliffe, DLA Piper Rudnick Gary Cary
Howard S. Schwartz, DLA Piper Rudnick Gary Cary

DUE DILIGENCE FOR UNIVERSITY COLLABORATIONS AND LICENSES
Mary Dicig, University of Illinois at Chicago

LIFE SCIENCES IP DUE DILIGENCE FOR INDUSTRY/UNIVERSITY COLLABORATIONS AND LICENSES
Eric J. Marandett, Choate, Hall & Stewart

PATENT-PROTECTED BIOPHARMACEUTICAL PRODUCTS: FITTING VALUATION INTO YOUR DUE DILIGENCE ASSESSMENTS
John R. Dwyer, Arent Fox PLLCD
Thomas McGahren, Merrill Lynch & Company
John R. Storella, Ciphergen Biosystems, Inc.

VALUATION OF PATENT PROTECTED BIOTECH PRODUCTS
Thomas McGahren, Merrill Lynch & Company

VALUATION AND IP DUE DILIGENCE
John R. Storella, Ciphergen Biosystems, Inc.

EARLY-STAGE VALUATION VS LATE-STAGE VALUATION OF COMPOUNDS AND COMPANIES
Matthew N. Murray, New York Private Equity

OVERCOMING ETHICAL CHALLENGES IN LIFE SCIENCES IP DUE DILIGENCE & VALUATION
John M. Naber, Dickinson Wright PLLC

WORKSHOP ON DRAFTING AN EFFECTIVE IP DUE DILIGENCE REPORT
Adda C. Gogoris, Darby & Darby



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0